Publications by authors named "M McJannett"
Background: Enzalutamide and lutetium-177 [Lu]Lu-prostate-specific membrane antigen (PSMA)-617 both improve overall survival in patients with metastatic castration-resistant prostate cancer. Androgen and PSMA receptors have a close intracellular relationship, with data suggesting complementary benefit if targeted concurrently. In this study, we assessed the activity and safety of enzalutamide plus adaptive-dosed [Lu]Lu-PSMA-617 versus enzalutamide alone as first-line treatment for metastatic castration-resistant prostate cancer.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess the effectiveness of adding ipilimumab to nivolumab treatment in patients with advanced, non-clear-cell renal cell carcinoma who showed disease progression on nivolumab alone.
- In a phase 2 trial, patients received nivolumab for up to 12 months, then ipilimumab if their condition worsened; the response rates were relatively low, with notable treatment-related adverse events.
- Despite modest overall effects of nivolumab alone, some participants did respond well, and the combination treatments continued to show some promise in managing the disease.
Background: Radiation may improve the efficacy of immune checkpoint inhibition. This study investigates the combination of pembrolizumab and chemoradiation (CRT) for muscle-invasive bladder cancer (MIBC).
Objective: To assess the feasibility and safety of pembrolizumab combined with CRT for MIBC.
Purpose: International guidelines advocate for active surveillance as the preferred treatment strategy for patients with stage 1 testicular cancer after orchidectomy although a personalized discussion is required.
Materials And Methods: We conducted an analysis of individuals registered in iTestis, Australia's testicular cancer registry, to describe the patterns of relapse and outcomes of patients treated in Australia where the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations are widely adopted.
Results: A total of 650 individuals diagnosed between 2000 and 2020 were included, 63% (411 of 650) seminoma and 37% (239 of 650) nonseminoma.